Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US
Pei PP, Weinstein MC, Li XC, Hughes MD, Paltiel AD, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, Walensky RP. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Research & Clinical Practice 2015, 16: 207-218. PMID: 26651525, PMCID: PMC4718767, DOI: 10.1080/15284336.2015.1123942.Peer-Reviewed Original ResearchConceptsGeneric antiretroviral therapyAntiretroviral therapyProbabilistic sensitivity analysesTreatment changesFirst-line ART regimensMore treatment changesComparative effectiveness trialTwo-arm trialImproved health outcomesTwo-pillART regimensHIV careART failureEffectiveness trialTrial completionRNA suppressionHealth outcomesFuture patientsPatientsCost-effective strategyTrialsRegimenRegimensHIVTherapyPrioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US
Pei P, Weinstein M, Li X, Hughes M, Paltiel A, Hou T, Parker R, Gaynes M, Sax P, Freedberg K, Schackman B, Walensky R. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Research & Clinical Practice 2015, 1945577115y.000. DOI: 10.1179/1945577115y.0000000009.Peer-Reviewed Original ResearchComparative effectiveness trialEffectiveness trial